19 Mar

Analysts Are Divided on Johnson & Johnson Stock

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts have given Johnson & Johnson (JNJ) a 12-month consensus target price of $144.71, 5.50% higher than the company’s closing price on March 18. The consensus analyst recommendation for the stock is a “buy.” Although analysts first revised the company’s target price downward from $145.50 in January to $144.22 in February, they raised it to $144.71 in March.

To learn about the key growth drivers and risks for Johnson & Johnson this year, read Here Are Some Possible Headwinds and Tailwinds for JNJ in 2019.

Analysts Are Divided on Johnson & Johnson Stock

Of the 18 analysts covering Johnson & Johnson, four analysts have given it “strong buys,” five have given it “buys,” eight have given it “holds,” and only one has given it a “sell.” The highest target price estimate for the company is $160, and the lowest is $123.

On March 18, Johnson & Johnson closed at $137.17, 0.31% lower than its previous closing price, 15.64% higher than its 52-week low of $118.62, and 7.93% lower than its 52-week high of $148.99. The company’s market cap is $366.42 billion.

Based on its closing price on March 18, Johnson & Johnson has reported returns of -1.00% in the last week, 2.13% in the last month, and -7.22% in the last quarter. The company has reported returns of -1.94% in the last half year, 3.09% in the last year, and 6.29% year-to-date.

Revenue and EPS estimates

Analysts expect Johnson & Johnson’s revenue to see YoY (year-over-year) changes of -1.94% to $19.62 billion in the first quarter, -1.93% to $20.43 billion in the second quarter, -0.96% to $20.15 billion in the third quarter, and 2.33% to $20.87 billion in the fourth quarter of 2019. Analysts also expect the company’s non-GAAP (generally accepted accounting principles) EPS to see YoY rises of 2.73% to $2.12 in the first quarter, 9.65% to $2.30 in the second quarter, 4.51% to $2.14 in the third quarter, and 2.28% to $2.01 in the fourth quarter.

Analysts expect Johnson & Johnson’s revenues to see YoY changes of -0.50% to $81.17 billion in 2019, 4.18% to $84.56 billion in 2020, and 4.37% to $88.26 billion in 2021. Analysts also expect the company’s non-GAAP EPS to see YoY rises of 4.93% to $8.58 in 2019, 5.76% to $9.08 in 2020, and 7.55% to $9.76 in 2021.

Latest articles

Aurora Cannabis (ACB) reported its first-quarter earnings of fiscal 2020 on November 14. The company reported revenues of $75.25 million Canadian dollars.

Recently, Democratic candidate Joe Biden explained why he opposes full-scale cannabis legalization. Candidate Cory Booker criticized his stance.

L Brands (LB) stock surged by 8.1% yesterday after the company's third-quarter earnings announcement on November 20. Here's why.

Tesla’s (TSLA) CEO Elon Musk finally revealed the Tesla truck, an electric pickup truck, yesterday at an event in Los Angeles.

Gap posted better-than-expected fiscal 2019 third-quarter earnings results on November 21. However, both its sales and earnings fell year-over-year.

Uber stock, which lost 15% in the first half of the month, gained 9% in the last three trading sessions, adding over $3.5 billion in investor wealth.